NeRRe Therapeutics Limited
9Patents
9Active
9Granted
43Portfolio score
Filing activity: Aug 25, 2010 → May 28, 2021 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8796269B2 | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same | Human Necessities | 6 | Active |
| US10195205B2 | Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases | Human Necessities | 4 | Active |
| US9603849B2 | Uses of orvepitant | Human Necessities | 3 | Active |
| US9750739B2 | Orvepitant for chronic cough therapy | Human Necessities | 1 | Active |
| US9006271B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | Human Necessities | 0 | Active |
| US9907795B2 | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | Human Necessities | 0 | Active |
| US8822504B2 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists | Human Necessities | 0 | Active |
| US8633214B2 | Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonists | Chemistry; Metallurgy | 0 | Active |
| US11872222B2 | Uses | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.